CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells

12Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity. The aim of this study was to assess the role of CYP11B1 on mitotane action and metabolism in H295R ACC cells to understand whether this enzyme may influence mitotane action. The simultaneous incubation with mitotane and metyrapone, an adrenolytic molecule targeting 11-beta-hydroxylase, did not influence mitotane-mediated cytotoxic effect and metabolism in H295R ACC cells. CYP11B1 silencing confirmed the lack of a significant metyrapone effect on mitotane action. The present findings do not support the view that CYP11B1 catalyzes a crucial step in the metabolic activation of mitotane and that CYP11B1 confers the adrenal specificity to mitotane.

Cite

CITATION STYLE

APA

Germano, A., Saba, L., De Francia, S., Rapa, I., Perotti, P., Berruti, A., … Terzolo, M. (2018). CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. PLoS ONE, 13(5). https://doi.org/10.1371/journal.pone.0196931

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free